Ignite Creation Date:
2024-05-05 @ 12:07 PM
Last Modification Date:
2024-10-26 @ 9:20 AM
Study NCT ID:
NCT00250861
Status:
TERMINATED
Last Update Posted:
2008-04-21
First Post:
2005-11-07
Brief Title:
Trial of Outpatient Immunotherapy With Rituximab and Aldesleukin IL-2 vs Rituximab Alone for Non-Hodgkins Lymphoma
Sponsor:
US Oncology Research
Organization:
US Oncology Research
Study Overview
Official Title:
A Randomized Phase II Trial of Outpatient Immunotherapy With Rituximab and Aldesleukin IL-2 vs Rituximab Alone for CD20 Positive Aggressive Non-Hodgkins Lymphoma Following High Dose Therapy With Autologous PBSC Rescue
Status:
TERMINATED
Status Verified Date:
2008-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Study terminated due to lack of enrollment
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this research study is to find out if treatment with rituximab in combination with aldesleukin compared to rituximab alone decreases the risk of cancer returning as well as determining what other effects good and bad this drug combination has on NHL Rituximab and aldesleukin are not approved in combination by the Food and Drug Administration FDA for the treatment of non-Hodgkins lymphoma however Rituximab is approved for use by itself to treat NHL
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None